New family of molecules with oral therapeutic potential in obesity, hepatic steatosis, NASH, hypertension, dyslipidemia and type 2 diabetes.

SJT Molecuar Research is a biotechnology company recognized by a prestigious team of collaborators, CROs and universities from several continents.

Innovation on Diabetes +

  • Efficacy comparable to reference antidiabetics (metformin, pioglitazone).
  • Glucose regulatory activity by insulin sensitization.
  • No detectable toxicity in animal models.
  • Worldwide patent protection.

Additional Information

  • Positive cardiovascular effects by reducing systolic arterial pressure.
  • Significant reduction of obesity.
  • Proved regulating effect in diabetes, hypertension, dyslipidemia, overweight, hepatic steatosis and NASH.
  • Simple method of synthesis with high yield and purity.
  • 3 compounds in pre-clinical development.


Worldwide protection of patent application PCT No. WO2012130912.

Currently we have been granted the national phases of this international patent application in:

In addition, the international patent request has entered the regional phase in China, Brazil, Canada and India among others.

The use of all the compounds is protected for the treatment of the metabolic syndrome in general and for specific etiologies associated with the syndrome including diabetes, hypertension, dyslipidemia, obesity, hepatic steatosis and NASH.